# Definium Therapeutics, Inc. (DFTX)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/definium-therapeutics-inc/ JSON: https://steadybase.io/company/definium-therapeutics-inc.json Checked Nov 21, 2026. Latest filing read: Nov 9, 2026.

## Company

- Legal name: Definium Therapeutics, Inc.
- Ticker: DFTX (Nasdaq)
- SEC CIK: 0001813814
- Industry: Medicinal Chemicals & Botanical Products (SIC 2833)
- Headquarters: New York, NY
- Fiscal year ends: December 31
- SEC filer category: <br>Emerging growth company
- Website: definiumtx.com
- Investor relations: https://ir.definiumtx.com
- LinkedIn: https://www.linkedin.com/company/definiumtherapeutics
- Next earnings date: Jan 18, 2027

## Key facts

- Operating income: -$166.3M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/0001193125-26-076742-index.html
- Net income: -$183.8M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/0001193125-26-076742-index.html
- SG&A: $48.6M for the fiscal year ended Dec 31, 2025 (10-K filed Feb 26, 2026). Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/0001193125-26-076742-index.html
- Employees: 105 as of Dec 31, 2025, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm
- Shares outstanding: 136,899,935 as of Nov 2, 2026 (10-Q filed Nov 9, 2026). Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312526453626/0001193125-26-453626-index.html
- Auditor: Kpmg LLP, San Diego, California, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm

## Business

We are a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to forge a new era of psychiatry by applying scientific rigor to psychedelics, with the goal of developing accessible treatments that unlock healing at scale. We are developing a pipeline of innovative product candidates targeting neurotransmitter pathways that play key roles in brain health disorders.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm

## Officers and directors

- Robert Barrow, Chief Executive Officer. LinkedIn: https://linkedin.com/in/robert-barrow-b50836a. Source: Form 4 filed Sep 29, 2026, https://www.sec.gov/Archives/edgar/data/1813814/000110465926112062/0001104659-26-112062-index.htm
- Brandi Roberts, Chief Financial Officer. LinkedIn: https://linkedin.com/in/brandi-roberts-sd. Source: Form 4 filed Sep 29, 2026, https://www.sec.gov/Archives/edgar/data/1813814/000110465926112058/0001104659-26-112058-index.htm
- Brandi L. Roberts, Chief Financial Officer. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm
- Daniel Karlin, Chief Medical Officer. Source: Form 4 filed Sep 29, 2026, https://www.sec.gov/Archives/edgar/data/1813814/000110465926112065/0001104659-26-112065-index.htm
- Mark Sullivan, Chief Legal Officer. Source: Form 4 filed Sep 29, 2026, https://www.sec.gov/Archives/edgar/data/1813814/000110465926112060/0001104659-26-112060-index.htm
- Matthew T. Wiley, Chief Commercial Officer. Source: Form 4 filed Sep 29, 2026, https://www.sec.gov/Archives/edgar/data/1813814/000110465926112061/0001104659-26-112061-index.htm
- Andreas Krebs, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm
- Carol Vallone, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm
- David Gryska, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm
- Roger Adsett, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm
- Roger Crystal, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm
- Suzanne Bruhn, Director. Source: 10-K filed Feb 26, 2026, https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm

## Recent 8-K events

- Nov 9, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312526453595/dftx-20261109.htm
- Sep 14, 2026: Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1813814/000110465926107275/tm2625365d1_8k.htm
- Sep 8, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312526384403/dftx-20260908.htm
- Aug 12, 2026: Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1813814/000110465926094528/tm2622948d1_8k.htm
- Aug 6, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312526338006/dftx-20260806.htm
- Jun 24, 2026: Item 1.01, Entry into a material definitive agreement; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1813814/000110465926077354/tm2618395d3_8k.htm
- Jun 22, 2026: Item 7.01, Regulation FD disclosure; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1813814/000110465926076091/tm2618434d1_8k.htm
- Jun 12, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312526269549/dftx-20260611.htm
- May 19, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312526229657/dftx-20260519.htm
- May 12, 2026: Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312526218251/dftx-20260512.htm

## Insider trades (Form 4)

- Sep 25, 2026: Daniel Karlin (Chief Medical Officer) sold 10,853 shares, about $396,894. Source: https://www.sec.gov/Archives/edgar/data/1813814/000110465926112065/0001104659-26-112065-index.htm
- Sep 25, 2026: Robert Barrow (Chief Executive Officer) sold 31,550 shares, about $1.2M. Source: https://www.sec.gov/Archives/edgar/data/1813814/000110465926112062/0001104659-26-112062-index.htm
- Sep 25, 2026: Matthew T. Wiley (Chief Commercial Officer) sold 3,097 shares, about $113,257. Source: https://www.sec.gov/Archives/edgar/data/1813814/000110465926112061/0001104659-26-112061-index.htm
- Sep 25, 2026: Mark Sullivan (Chief Legal Officer) sold 14,051 shares, about $513,845. Source: https://www.sec.gov/Archives/edgar/data/1813814/000110465926112060/0001104659-26-112060-index.htm
- Sep 25, 2026: Brandi Roberts (Chief Financial Officer) sold 3,377 shares, about $123,497. Source: https://www.sec.gov/Archives/edgar/data/1813814/000110465926112058/0001104659-26-112058-index.htm
- Sep 3, 2026: Robert Barrow (Chief Executive Officer) sold 19,023 shares, about $721,733. Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312526384042/0001193125-26-384042-index.htm
- Jun 25, 2026: Mark Sullivan (Chief Legal Officer) sold 13,008 shares, about $585,750. Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312526285567/0001193125-26-285567-index.htm
- Jun 25, 2026: Daniel Karlin (Chief Medical Officer) sold 10,035 shares, about $451,876. Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312526285564/0001193125-26-285564-index.htm
- Jun 25, 2026: Brandi Roberts (Chief Financial Officer) sold 3,013 shares, about $135,675. Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312526285563/0001193125-26-285563-index.htm
- Jun 25, 2026: Robert Barrow (Chief Executive Officer) sold 29,208 shares, about $1.3M. Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312526285562/0001193125-26-285562-index.htm
- Jun 25, 2026: Matthew T. Wiley (Chief Commercial Officer) sold 2,867 shares, about $129,101. Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312526285558/0001193125-26-285558-index.htm
- Mar 25, 2026: Daniel Karlin (Chief Medical Officer) sold 8,018 shares, about $148,092. Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312526126830/0001193125-26-126830-index.htm
- Mar 25, 2026: Mark Sullivan (Chief Legal Officer) sold 10,702 shares, about $197,666. Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312526126827/0001193125-26-126827-index.htm
- Mar 25, 2026: Robert Barrow (Chief Executive Officer) sold 24,431 shares, about $451,241. Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312526126825/0001193125-26-126825-index.htm
- Dec 26, 2025: Daniel Karlin (Chief Medical Officer) sold 5,600 shares, about $73,640. Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312525335484/0001193125-25-335484-index.htm

## What management said

- "Our positive Phase 3 topline results from Voyage and Panorama this quarter further strengthened the evidence supporting DT120 ODT. Together with our previously reported results, these findings demonstrate consistent, clinically meaningful results across three Phase 3 studies in GAD and MDD, reinforcing our confidence in DT120 ODT’s potential to address significant unmet needs across both conditions" Rob Barrow, Chief Executive Officer (8-K filed Nov 9, 2026). Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312526453595/dftx-ex99_1.htm
- "The second quarter marked a meaningful inflection point for Definium as we further established our leadership position in psychedelic medicine" Rob Barrow, Chief Executive Officer of Definium Therapeutics (8-K filed Aug 6, 2026). Source: https://www.sec.gov/Archives/edgar/data/1813814/000119312526338006/dftx-ex99_1.htm

## Latest filings

- 8-K filed Sep 14, 2026: https://www.sec.gov/Archives/edgar/data/1813814/000110465926107275/tm2625365d1_8k.htm
- 10-K filed Feb 26, 2026: https://www.sec.gov/Archives/edgar/data/1813814/000119312526076742/dftx-20251231.htm
- 10-Q filed Aug 6, 2026: https://www.sec.gov/Archives/edgar/data/1813814/000119312526338066/dftx-20260630.htm
- DEF 14A filed Apr 27, 2026: https://www.sec.gov/Archives/edgar/data/1813814/000119312526182034/dftx-20260427.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/

